Financial Performance - The company's operating revenue for the first half of 2022 was approximately CNY 636.51 million, a decrease of 17.00% compared to CNY 766.92 million in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2022 was CNY 125.22 million, representing an increase of 7.01% from CNY 117.01 million in the previous year[19]. - The basic earnings per share for the first half of 2022 was CNY 0.1037, up 7.02% from CNY 0.0969 in the same period last year[19]. - The weighted average return on equity increased to 2.99% from 2.75% year-on-year, reflecting a growth of 0.23 percentage points[19]. - The company reported a net profit of CNY 121.88 million after deducting non-recurring gains and losses, which is a 14.67% increase from CNY 106.30 million in the same period last year[19]. - The company achieved a total revenue of 636.51 million yuan, a year-on-year decrease of 17.00%, while net profit increased by 7.01% to 125.22 million yuan[27]. - The company reported a significant increase in other receivables, which rose to ¥97,431,316.00 from ¥28,733,212.38, a growth of approximately 238.5%[95]. - The company reported a net profit from its major subsidiaries, with Jiangxi Gannan Haixin Pharmaceuticals achieving a net profit of CNY 16,796,322.90[42]. Cash Flow and Assets - The net cash flow from operating activities decreased by 95.38%, down to CNY 10.39 million from CNY 225.01 million in the same period last year, primarily due to sales returns from the previous year's land sales[19]. - The company's cash and cash equivalents increased to ¥373,386,172.34 from ¥320,121,753.57, representing a growth of approximately 16.6%[95]. - Total current assets reached ¥1,061,400,732.96, up from ¥913,297,707.32, reflecting a growth of approximately 16.2%[95]. - Total assets decreased from CNY 5,325,619,470.52 to CNY 5,101,177,496.70, a decline of approximately 4.22%[96]. - The total assets of the company at the end of the reporting period were not explicitly stated but can be inferred from the equity figures provided[122]. Segment Performance - The pharmaceutical segment generated a combined revenue of 385.16 million yuan, down 10.27% year-on-year, but net profit rose significantly by 59.37% to 11.03 million yuan[27]. - The property leasing segment reported revenue of approximately 45.80 million yuan, an increase of 3.11% year-on-year, with net profit rising by 17.87% to 26.95 million yuan[29]. - The textile segment achieved revenue of 105.52 million yuan, a year-on-year increase of 10.31%, although it reported a net loss of 3.23 million yuan, worsening by 100.15% compared to the previous year[30]. Environmental Compliance - The company’s wastewater treatment facilities have consistently met discharge standards without exceeding limits for various pollutants[59]. - The company’s environmental compliance includes maintaining emissions below regulatory thresholds for volatile organic compounds and particulate matter[59]. - The company has implemented measures to ensure that all emissions are within regulatory limits, with most pollutants reported as not exceeding standards[60]. - The company has received an administrative penalty of 31,989 yuan for violating environmental impact assessment regulations in April 2022[70]. - The company operates under valid pollution discharge permits, with the latest for Baoding Changmaorong valid until January 16, 2026[66]. Governance and Management - The company has implemented measures to enhance management governance and optimize internal control systems to improve operational efficiency[32]. - The company experienced a change in senior management with the resignation of the vice president, Bao Sui[52]. - The company’s governance practices were reviewed and approved during the annual shareholder meeting held on June 23, 2022[50]. Strategic Initiatives - The company is actively pursuing the "G60 Zhejiang Science and Technology Base" project, with the goal of achieving the opening of the first phase by the end of the year[31]. - The company plans to continue focusing on market expansion and new product development to drive future growth[106]. Risks and Challenges - The company faces market risks due to intense competition in its pharmaceutical and textile businesses, which may significantly impact performance[44]. - Policy risks, including stricter environmental regulations and changes in healthcare policies, may affect the company's pharmaceutical manufacturing operations[45]. - The ongoing pandemic continues to introduce uncertainties in production and operations, impacting the macroeconomic and policy environment[47]. Financial Reporting and Accounting - The financial statements are prepared based on the enterprise accounting standards, reflecting the company's financial status and operating results accurately[131]. - The company recognizes expected credit losses for financial assets measured at amortized cost and those measured at fair value through other comprehensive income[157]. - The company measures expected credit losses for financial assets based on the present value of the difference between contractual cash flows received and expected cash flows[159]. - The company recognizes gains or losses from financial assets measured at fair value through profit or loss, unless they fall under specific exceptions[164].

Financial Performance - In 2021, the company achieved a total revenue of CNY 1,511,255,284.73, representing a 62.03% increase compared to CNY 932,727,985.27 in 2020[24]. - The net profit attributable to shareholders was CNY 132,091,780.53, which is a 10.64% increase from CNY 119,391,753.57 in the previous year[24]. - The net profit after deducting non-recurring gains and losses was CNY 103,858,333.22, reflecting a 14.69% increase from CNY 90,558,477.79 in 2020[24]. - The cash flow from operating activities increased by 79.31% to CNY 219,647,104.26, up from CNY 122,499,034.51 in 2020[24]. - The company achieved an operating revenue of 1.511 billion yuan in 2021, representing a year-on-year growth of 62.03%[33]. - The net profit for 2021 was 132 million yuan, an increase of 10.64% compared to the previous year[33]. - The weighted average return on equity rose to 3.12%, up from 2.98% in the previous year[28]. - The basic earnings per share increased to 0.1094 yuan, marking a growth of 10.62% year-on-year[28]. Segment Performance - The pharmaceutical segment generated revenue of 872.99 million yuan, a year-on-year increase of 36.35%[34]. - The revenue from the Gannan Haixin segment reached 595.90 million yuan, growing by 81.72% year-on-year[34]. - The property segment achieved rental income of 71.62 million yuan, reflecting an 18.24% increase from the previous year[35]. - The textile segment accelerated its adjustment, achieving revenue of 204.7 million yuan, a year-on-year decrease of 11.54%, with a consolidated net loss of 3.87 million yuan, improving by 32.44 million yuan year-on-year[36]. - The pharmaceutical manufacturing and sales segment generated a consolidated revenue of 872.99 million RMB, up 36.35% year-on-year, with a net profit of 14.13 million RMB[48]. - The property management segment achieved rental income of 71.62 million RMB, a growth of 18.24% year-on-year, with a net profit of 40.48 million RMB[48]. Assets and Liabilities - As of the end of 2021, the total assets amounted to CNY 5,325,619,470.52, a decrease of 5.32% from CNY 5,625,066,071.47 at the end of 2020[24]. - The company's net assets attributable to shareholders were CNY 4,128,288,109.68, showing a slight decrease of 1.45% from CNY 4,189,071,328.66 in 2020[24]. - The company had a total asset value of 5.326 billion RMB at the end of 2021, a decrease of 5.32% year-on-year, primarily due to a decline in the market value of Changjiang Securities[48]. - The company holds overseas assets valued at RMB 92.91 million, which constitutes 1.74% of total assets[70]. Cash Flow and Investments - The cash flow from investment income increased by 30.34% to ¥122,034,892.62, reflecting higher dividends received compared to the previous year[66]. - The company's investment activities resulted in a net cash outflow of 64.16 million RMB, while financing activities saw a net cash outflow of 231.25 million RMB, a significant increase of 317.58% year-on-year[49]. - The company achieved a revenue of 6.74 million yuan from financial investments, including activities related to Jiangsu Securities stocks and new stock subscriptions[40]. - The company has significant investments in structured deposits, with a total initial investment of RMB 240.50 million and a year-end book value of RMB 240.50 million, resulting in a report period profit of RMB 5.58 million[73]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, and operates under established rules to ensure effective governance[97]. - The supervisory board is composed of 2 supervisors and 1 employee supervisor, adhering to legal requirements and effectively overseeing financial compliance[98]. - The company has established a performance evaluation and incentive mechanism linking senior management compensation to company and individual performance[99]. - The company has implemented an information disclosure management system to ensure timely and accurate information dissemination to all shareholders[100]. - The company has established four specialized committees under the board to enhance decision-making efficiency and governance[97]. Risk Management - The company has outlined potential risks in its future development strategies, which investors should be aware of[11]. - The company faces market risks due to intense competition in its pharmaceutical and textile sectors, which could significantly impact performance[88]. - Regulatory risks from stricter environmental policies and changes in healthcare regulations may affect the company's operations in the pharmaceutical and textile sectors[89]. - The company has a structured approach to risk management and compliance, with key personnel holding multiple roles in financial and asset management sectors[115]. Environmental Compliance - The company has successfully maintained ammonia emissions below 4.9 kg/h, adhering to the standards set by GB14554-93[146]. - The concentration of particulate matter from the exhaust is controlled to be less than 120 mg/Nm3, ensuring compliance with air pollution standards[146]. - The wastewater treatment process has a biochemical oxygen demand (BOD) limit of ≤500 mg/L, which is consistently met[146]. - The company reported that the concentration of sulfur dioxide emissions from boiler exhaust is maintained below 300 mg/Nm3, complying with GB13271-2014 standards[145]. - The company has reported no exceedances in the emission limits for all monitored pollutants, demonstrating effective environmental management practices[146]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 63,932, an increase from 63,644 in the previous month[178]. - The largest shareholder, Shenzhen Ningrui Investment Management, holds 141,528,801 shares, representing 11.73% of the total shares[180]. - The second-largest shareholder, Shanghai Songjiang Dongjing Industrial Company, holds 82,082,000 shares, accounting for 6.80%[180]. - The company has not reported any changes in its total share capital or share structure during the reporting period[176]. Strategic Focus - The company plans to continue expanding its market presence and enhancing product quality in response to changing economic conditions and consumer demands[33]. - The company is focusing on strategic planning for the "14th Five-Year Plan," emphasizing revitalizing existing assets and strengthening core businesses, particularly in the pharmaceutical and property sectors[41]. - The company aims to implement a "large property and asset management" model, transitioning from basic property leasing to comprehensive property services and asset management[84]. - The strategic focus includes leveraging new emerging industries and aligning with national policies to support sustainable development and transformation[83].

Financial Performance - The company's operating revenue for Q3 2021 was ¥328,490,601.12, representing a year-on-year increase of 5.80%[3] - The net profit attributable to shareholders for the same period was ¥32,406,549.88, up 12.01% compared to the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached ¥32,371,493.52, reflecting an 18.12% increase year-on-year[3] - Total operating revenue for the first three quarters of 2021 reached ¥1,095,415,385.72, a significant increase from ¥738,457,035.94 in the same period of 2020, representing a growth of approximately 48.5%[15] - Net profit for the first three quarters of 2021 was ¥153,679,362.35, up from ¥116,164,146.80 in 2020, reflecting a growth of approximately 32.3%[16] - Earnings per share for the first three quarters of 2021 were ¥0.1238, compared to ¥0.1001 in the same period of 2020, marking an increase of about 23.7%[17] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥221,925,345.73, showing a significant increase of 307.39%[3] - Cash flow from operating activities for the first three quarters of 2021 was ¥1,134,547,722.96, compared to ¥841,174,931.61 in 2020, showing an increase of approximately 34.8%[18] - Net cash inflow from operating activities was $221,925,345.73, a significant increase compared to $54,474,582.46 in the previous year, representing a growth of approximately 307%[19] - Total cash outflow for operating activities was $976,767,046.66, an increase from $870,838,760.49, reflecting a rise of approximately 12%[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,426,924,104.70, a decrease of 3.52% from the end of the previous year[4] - The company's total assets amounted to ¥5,426,924,104.70 as of the end of the third quarter of 2021, down from ¥5,625,066,071.47 at the end of the same period in 2020[14] - The company's current assets totaled ¥965,646,711.95, an increase from ¥834,890,087.59 in the previous year[12] - The company's total liabilities decreased to ¥1,069,305,893.56 from ¥1,245,567,071.88, reflecting a reduction of about 14.2%[13] - The non-current assets were reported at ¥4,461,277,392.75, down from ¥4,790,175,983.88, showing a decline of approximately 6.9%[12] - The company's equity remained stable at ¥1,207,056,692.00, unchanged from the previous year[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 62,591, with 29,693 A-share and 32,898 B-share holders[8] - The top shareholder, Shenzhen Ningrui Investment Management Enterprise, held 141,528,801 shares, accounting for 11.73% of the total shares[8] Project Performance - The company reported a significant increase in revenue from the Haixin Zhihui project, contributing ¥202 million to the total revenue[6] - The net profit from the Haixin Zhihui project delivery was ¥14.0862 million, contributing positively to the overall profit[6] Research and Development - Research and development expenses for the first three quarters of 2021 were ¥14,528,317.02, compared to ¥13,196,580.82 in 2020, indicating an increase of about 10.1%[15] Investment Income - The company reported investment income of ¥134,915,654.85 for the first three quarters of 2021, compared to ¥127,823,448.66 in 2020, reflecting a growth of approximately 5.5%[16]

Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥766.92 million, representing a 79.20% increase compared to ¥427.96 million in the same period last year[20]. - The net profit attributable to shareholders for the first half of 2021 was approximately ¥117.01 million, an increase of 27.31% from ¥91.91 million in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥106.30 million, reflecting a 43.73% increase from ¥73.95 million in the same period last year[20]. - The net cash flow from operating activities increased significantly to approximately ¥225.01 million, compared to only ¥2.87 million in the same period last year, marking a 7,739.86% increase[20]. - The company achieved a revenue of 767 million yuan, representing a year-on-year growth of 79.20%[28]. - The net profit attributable to shareholders reached 117 million yuan, an increase of 27.31% compared to the previous year[28]. - The pharmaceutical segment generated a revenue of 429 million yuan, up 40.96% year-on-year, with a net profit of 22.73 million yuan, growing by 103.07%[28]. - The company reported a significant increase in sales revenue from the Haixin Zhihui project, contributing approximately ¥202 million, and an increase of ¥136 million from Gannan Haixin sales compared to the previous year[20]. Assets and Liabilities - The net assets attributable to shareholders at the end of the reporting period were approximately ¥4.07 billion, a decrease of 2.90% from ¥4.19 billion at the end of the previous year[20]. - Total assets decreased by 5.06% to approximately ¥5.34 billion from ¥5.63 billion at the end of the previous year[20]. - The company's total assets at the end of the reporting period amount to CNY 4,067,746,448.75, compared to CNY 4,048,476,929.57 at the end of the previous year, indicating a growth of approximately 0.5%[124]. - Total liabilities decreased to ¥1,079,790,068.93, down 13.31% from ¥1,245,567,071.88[97]. - The company's equity attributable to shareholders decreased to ¥4,067,746,448.75 from ¥4,189,071,328.66, a decline of 2.91%[97]. Cash Flow - The company reported a cash inflow from investment activities of CNY 340,583,040.94, compared to CNY 242,192,036.61 in the same period of 2020, showing an increase of 40.6%[113]. - The cash flow from financing activities resulted in a net outflow of CNY -174,676,513.41, a decrease from a net inflow of CNY 19,627,535.67 in the first half of 2020[113]. - The net increase in cash and cash equivalents for the first half of 2021 was 3,924,430.16 RMB, a significant improvement from a decrease of -56,927,031.94 RMB in the same period of 2020[117]. - The total cash and cash equivalents at the end of the first half of 2021 stood at 156,445,667.09 RMB, compared to 28,684,335.17 RMB at the end of the first half of 2020, indicating a substantial increase[117]. Research and Development - Research and development expenses increased by 32.20% to approximately ¥10.24 million, reflecting the company's commitment to innovation[40]. - The company is actively expanding its pharmaceutical product line, adding 52 new sales products and 2 new product agencies[29]. - The company is advancing the development of several generic drugs, including Azithromycin and Dexmedetomidine, with ongoing clinical trials[30]. Environmental Compliance - The company has not reported any exceedance in emissions for various pollutants, including ammonia nitrogen and total phosphorus[62][63]. - The company adheres to multiple environmental standards, including GB 4287-2012 for textile dyeing and finishing wastewater[62]. - The company maintains compliance with air quality standards for emissions from its facilities, including limits on sulfur dioxide and nitrogen oxides[63]. - Overall, the company demonstrates a commitment to environmental compliance with no reported exceedances in key pollutant categories[61][62][63]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 64,722, with 31,511 holding A shares and 33,211 holding B shares[87]. - The top shareholder, Shenzhen Ningrui Investment Management Enterprise, holds 141,528,801 shares, representing 11.73% of total shares[89]. - The total number of shares held by the top ten shareholders indicates a significant concentration of ownership, with the top three shareholders alone holding over 23.5%[89]. Risks - The company faces market risks due to intense competition in the textile and pharmaceutical sectors, which may significantly impact performance[48]. - Policy risks include stricter environmental regulations affecting the long plush and pharmaceutical manufacturing businesses[49]. - Financial risks are present due to the capital-intensive nature of the textile, pharmaceutical, and park transformation businesses[51]. Profit Distribution - The company has not disclosed any plans for profit distribution or capital increase from reserves during this reporting period[6]. - The company reported a profit distribution of CNY 36,211,700.76 to shareholders, indicating a reduction in retained earnings[126]. Accounting Practices - The company operates under the Chinese accounting standards, ensuring compliance and transparency in its financial reporting[138]. - The company recognizes unrealized internal transaction gains and losses from asset sales between itself and subsidiaries, fully offsetting the "net profit attributable to the parent company"[150].